"Metabolic Clearance Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site.
| Descriptor ID |
D008657
|
| MeSH Number(s) |
E01.370.225.843 E05.200.843 G03.490 G07.690.595 G07.690.725.513
|
| Concept/Terms |
Metabolic Clearance Rate- Metabolic Clearance Rate
- Clearance Rate, Metabolic
- Clearance Rates, Metabolic
- Metabolic Clearance Rates
- Rate, Metabolic Clearance
- Rates, Metabolic Clearance
|
Below are MeSH descriptors whose meaning is more general than "Metabolic Clearance Rate".
Below are MeSH descriptors whose meaning is more specific than "Metabolic Clearance Rate".
This graph shows the total number of publications written about "Metabolic Clearance Rate" by people in this website by year, and whether "Metabolic Clearance Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 10 | 10 |
| 2018 | 2 | 10 | 12 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Metabolic Clearance Rate" by people in Profiles.
-
Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment. Medicine (Baltimore). 2021 Jun 04; 100(22):e26253.
-
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet. 2021 05; 60(5):569-583.
-
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. Am J Cardiovasc Drugs. 2020 Dec; 20(6):525-533.
-
Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. Eur J Clin Pharmacol. 2021 Apr; 77(4):583-593.
-
Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2. Clin Pharmacol Ther. 2020 12; 108(6):1176-1184.
-
Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6. Clin Pharmacokinet. 2020 10; 59(10):1251-1260.
-
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. Pharmacotherapy. 2020 08; 40(8):843-856.
-
Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. Clin Pharmacol Ther. 2020 11; 108(5):976-984.
-
Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance! Crit Care. 2020 06 10; 24(1):325.
-
Glomerular Hyper- and Hypofiltration During Acute Circulatory Failure: Iohexol-Based Gold-Standard Descriptive Study. Crit Care Med. 2019 08; 47(8):e623-e629.